NEW YORK, July 15, 2002 (PRIMEZONE) -- Alvin Glasky, Chairman and CEO of NeoTherapeutics, Inc. (Nasdaq:NEOT) commences the interview with a discussion of the advantages of using third party companies to conduct clinical trials and the manner in which the Company has been minimizing costs and diminishing burn rates. With decreased workforce there is a danger of slowing key projects, Dr. Glasky explains how he has overcome this hurdle.
We then look at the Company's new lead drug Neotrofin and the manner in which they will conduct their trials and how they will finance this most costly aspect of drug development. We then discuss the value of robotics and computers in primary research and where they are most effectively used within biotech companies.
The substantial share volume increase over the last two months is then explained along with how Dr. Glasky sees the lessening focus on Alzheimer's treatment as being advantageous for his company. The interview is closed on the therapeutic drug development pipeline with a focus on Neotrofin. Finally, we look at the recent financing that the company received Friday and the reasoning behind this investment.
The interview can be heard at www.wallst.net
About NeoTherapeutics, Inc.
NeoTherapeutics seeks to create value for stockholders through the discovery and out-licensing of drugs for central nervous system disorders, the in-licensing and commercialization of anti-cancer drugs, and the out-licensing of new drug targets discovered through genomics research. Neotrofin(TM) is in clinical development in Parkinson's disease, spinal cord injury and chemotherapy-induced neuropathy. The Company's lead oncology drug, Satraplatin, is being prepared for a phase 3 study in prostate cancer. Additional anti-cancer drugs are in phase 1 and 2 human clinical trials, and the Company has a rich pipeline of pre-clinical neurological drug candidates.
About WallSt.net
The Wall St. Network (www.wallst.net) is a multimedia provider of original, insightful, commentary and news from North America's leading companies. Giving a direct link to the management of today's fastest growing companies through encompassing executive interviews and Sector Seminars.